FDA approves long-acting formulation of J&J schizophrenia med

The FDA gave the green light to Johnson & Johnson's ($JNJ) Invega Trinza, which is injected four times a year, making it the longest-acting schizophrenia drug on the market. Previous formulation Invega Sustenna earned $1.5 billion in 2014, so Invega Trinza is likely to become a blockbuster. More